News

After the Fall

Science  23 Mar 2001:
Vol. 291, Issue 5512, pp. 2340-2341
DOI: 10.1126/science.291.5512.2340b

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

In the early 1990s, two start-ups pushed new sugar-based drugs into late-stage clinical trials that promised to usher in a new era of compounds targeting sugars and sugar-binding proteins, which together play key roles in infections, cancer metastasis, and immune system diseases. But both drugs faltered, souring many investors and major pharmaceutical companies on the idea that sugars would make good drugs. Now carbohydrate specialists say biotech companies and a few venturesome pharmaceutical giants are regaining a bit of a sweet tooth.

Related Content